Frank Aquila, Ari Blaut and Davis Wang have been named “Dealmakers of the Year” by The American Lawyer for advising Amgen on its pending $28 billion acquisition of Horizon Therapeutics, the largest life sciences acquisition announced in 2022. Negotiating the complex, cross-border transaction required working at a breakneck pace to top an earlier unsolicited bid from Sanofi. This marks the third time that Frank, S&C’s Senior M&A Partner, has received this distinction, and the first time for Ari, Co-Head of S&C’s U.S. Credit & Leveraged Finance practice, and Davis, Co-Head of the Firm’s Tax practice.
This deal reflects S&C’s dominance in the healthcare sector. In 2022, the Firm advised on Abiomed’s $18 billion acquisition by Johnson & Johnson, Biohaven Pharmaceuticals’ $11.6 billion acquisition by Pfizer and Haleon's demerger from GSK, which created the world's biggest stand-alone consumer health company.
S&C lawyers have been named “Dealmakers of the Year” by The American Lawyer 26 times in the past 25 years, the most of any law firm.
Read our profile.